CLINICAL TRIALS PROFILE FOR ABOBOTULINUMTOXINA

All Clinical Trials for abobotulinumtoxina

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00257660 ↗	Randomized, Placebo-Controlled Study of AbobotulinumtoxinA (Dysport®) for the Treatment of Cervical Dystonia	Completed	Ipsen	Phase 3	2005-10-10	The aim of this study is to demonstrate the effectiveness and safety of 500 units of Dysport manufactured at a new manufacturing facility in Europe.
NCT00288509 ↗	Open-label Extension Study of AbobotulinumtoxinA (Dysport®) for the Treatment of Cervical Dystonia	Completed	Ipsen	Phase 3	2006-02-01	The aim of this study is to assess longer term safety and effectiveness of Dysport®.
NCT01459666 ↗	Forehead Scars Following Mohs Micrographic Surgery and Reconstruction for Skin Cancer	Terminated	Medicis Pharmaceutical Corporation	Phase 4	2011-09-01	This study will test if the use of DysportTM (abobotulinumtoxinA) improves wound healing and scarring after Mohs surgery. Research in the laboratory as well as previous studies in humans have shown improved wound healing and scarring with the use of a similar medication called Botox. Dysport may improve wound healing and scarring by relaxing facial muscles and therefore minimizes the muscle tension and possibly the inflammation around the wound.
NCT01459666 ↗	Forehead Scars Following Mohs Micrographic Surgery and Reconstruction for Skin Cancer	Terminated	University Hospitals Cleveland Medical Center	Phase 4	2011-09-01	This study will test if the use of DysportTM (abobotulinumtoxinA) improves wound healing and scarring after Mohs surgery. Research in the laboratory as well as previous studies in humans have shown improved wound healing and scarring with the use of a similar medication called Botox. Dysport may improve wound healing and scarring by relaxing facial muscles and therefore minimizes the muscle tension and possibly the inflammation around the wound.
NCT01459666 ↗	Forehead Scars Following Mohs Micrographic Surgery and Reconstruction for Skin Cancer	Terminated	AboutSkin Dermatology and DermSurgery, PC	Phase 4	2011-09-01	This study will test if the use of DysportTM (abobotulinumtoxinA) improves wound healing and scarring after Mohs surgery. Research in the laboratory as well as previous studies in humans have shown improved wound healing and scarring with the use of a similar medication called Botox. Dysport may improve wound healing and scarring by relaxing facial muscles and therefore minimizes the muscle tension and possibly the inflammation around the wound.
NCT01732809 ↗	Fields Of Effects Of Two Commercial Preparations Of Botulinum Toxin Type A At Equal Labeled Unit Doses	Completed	Brazilan Center for Studies in Dermatology	Phase 4	2011-01-01	The purpose of this study is to assess the fields of anhydrotic effect (FAE) of abobotulinumtoxinA and onabotulinumtoxinA at the same labeled unit dose (1:1 units), comparing both sweat gland and muscle activity.
NCT01921270 ↗	Dysport for the Treatment of OMD	Completed	Ipsen	Phase 1/Phase 2	2013-08-01	The purpose of this study is to study the efficacy and safety of AbobotulinumtoxinA (Dysport) for use in Oromandibular Dystonia (OMD).

Clinical Trial Conditions for abobotulinumtoxina

Condition Name

Condition Name for abobotulinumtoxina
Intervention	Trials
Scar	3
Overactive Bladder	3
Cervical Dystonia	3
Pain	2

Condition MeSH

Condition MeSH for abobotulinumtoxina
Intervention	Trials
Dystonia	5
Dystonic Disorders	4
Muscle Spasticity	4
Cerebral Palsy	3

Clinical Trial Locations for abobotulinumtoxina

Trials by Country

Trials by Country for abobotulinumtoxina
Location	Trials
United States	75
Brazil	4
Russian Federation	3
Israel	2
Spain	2

Trials by US State

Trials by US State for abobotulinumtoxina
Location	Trials
Michigan	6
California	6
Pennsylvania	5
New York	5
Florida	5

Clinical Trial Progress for abobotulinumtoxina

Clinical Trial Phase

Clinical Trial Phase for abobotulinumtoxina
Clinical Trial Phase	Trials
PHASE4	2
PHASE3	1
Phase 4	12

Clinical Trial Status

Clinical Trial Status for abobotulinumtoxina
Clinical Trial Phase	Trials
COMPLETED	12
Not yet recruiting	7
Terminated	6

Clinical Trial Sponsors for abobotulinumtoxina

Sponsor Name

Sponsor Name for abobotulinumtoxina
Sponsor	Trials
Ipsen	10
Western University, Canada	2
St Joseph University, Beirut, Lebanon	2

Sponsor Type

Sponsor Type for abobotulinumtoxina
Sponsor	Trials
Other	30
Industry	16
U.S. Fed	1

Abobotulinumtoxina (abobotulinumtoxinA) — Clinical Trials Update, Market Analysis, and Projection

Last updated: May 7, 2026

What is abobotulinumtoxina and where is it positioned clinically?

AbobotulinumtoxinA (abobotulinumtoxina; commonly marketed as Dysport in multiple geographies) is an injectable botulinum neurotoxin type A used for focal neuromuscular indications and cosmetic applications. Commercial adoption is supported by established administration protocols, broad physician familiarity, and a label footprint concentrated in neurology, spasticity, ophthalmology, and aesthetics.

What does the clinical trials pipeline look like by indication?

A complete, trial-by-trial pipeline update requires a verified, current clinical-trials dataset for abobotulinumtoxina across registries (ClinicalTrials.gov, EU CTR, WHO ICTRP). With no accessible trial registry payload in this chat context, a precise pipeline summary (trial phase, endpoints, dates, and results) cannot be produced without risking inaccuracies.

What is the current market landscape?

Abobotulinumtoxina competes in a global botulinum toxin type A market that includes branded products with overlapping indications. In practice, market share is influenced by: (1) indication coverage and dosing conversion familiarity, (2) safety and tolerability profile in real-world use, (3) physician training and injection patterns, (4) payer and reimbursement dynamics, and (5) product availability and commercial contracting.

Commercial drivers specific to abobotulinumtoxina

• Neuromuscular demand persistence: Chronic, recurrent treatments support recurring revenue cycles in focal spasticity and related conditions.
• Aesthetic use-through: Botulinum toxin A demand in facial aesthetics is sensitive to discretionary spend but also benefits from procedure standardization.
• Physician inertia: Established injection methods and conversion familiarity can reduce switching friction.

Key competitive context (high level)

The market includes multiple botulinum toxin type A products. In most geographies, competition centers on comparative effectiveness perceptions, cost-per-unit economics, and brand-level penetration.

What is the market size and growth outlook?

A defensible market forecast requires numeric baselines (global and regional market size), forecast horizon, and attribution assumptions (dose units, penetration rates, indication mix). No market-size dataset is present in this chat context, and generating figures without a source would violate the requirement for hard data.

What projection can be made for abobotulinumtoxina without external datasets?

No projection with hard numbers (revenue, unit volumes, CAGR, peak sales timing) can be produced accurately from the information available in this chat. A projection would require at minimum: (1) current sales or unit volume by geography, (2) uptake trends by indication, (3) pipeline and lifecycle events that affect label expansion or erosion, and (4) pricing and reimbursement data.

What are the highest-value commercial risks and levers?

Even without numeric market forecasts, the commercial levers and risk categories that typically move outcomes for botulinum toxin A products are measurable at execution level.

Primary levers

• Indication coverage depth: Expanded label indications can broaden prescriber base and reduce seasonality.
• Access and reimbursement: Contracting and payer positioning can shift utilization toward lower net acquisition cost.
• Training and standardization: Consistency in dosing practices can improve treatment experience and adherence to retreatment schedules.
• Manufacturing reliability: Botulinum toxins are supply-sensitive; continuity affects market confidence.

Primary risks

• Safety perception and adverse event management: Injection-site or systemic adverse event narratives can impact utilization.
• Pricing pressure from competitive entries: Net price compression can outpace unit growth.
• Regulatory and pharmacovigilance outcomes: Label updates tied to safety findings can change practice patterns.
• Treatment pattern shifts: Changes in clinical guidelines or physician preference can alter unit demand.

What to watch next in clinical development and regulatory activity?

A targeted watchlist must include actual upcoming milestones (trial readouts, phase transitions, label submissions, and guidance outcomes). No trial registries or regulatory event feeds are available in this chat context, so a date-driven milestone watchlist cannot be generated.

Key Takeaways

• Abobotulinumtoxina is a mature botulinum toxin type A product with established use across focal neuromuscular and aesthetics-adjacent pathways.
• A complete clinical trials update with phases, endpoints, and timelines cannot be produced from the current chat context without trial registry data.
• A numeric market analysis and projection (size, CAGR, peak sales timing, and sales path) cannot be produced accurately without sourced market and commercial datasets.
• Business-relevant traction for abobotulinumtoxina typically hinges on indication coverage depth, reimbursement access, physician training and standardization, and supply reliability; principal risks are safety perception, pricing pressure, and regulatory outcomes.

FAQs

1. What is abobotulinumtoxina used for?
   It is a botulinum neurotoxin type A injectable used for focal neuromuscular and related clinical indications and for aesthetic applications in marketed geographies.

2. Is there an ongoing clinical pipeline for abobotulinumtoxina?
   Clinical development activity exists for abobotulinumtoxina broadly across indications, but a specific current-phase update with endpoints and timelines requires registry data not present in this chat context.

3. What drives abobotulinumtoxina sales growth?
   Indication coverage, physician adoption, reimbursement and contracting, training and dosing standardization, and treatment retreatment patterns are the primary demand drivers.

4. What are the biggest market risks for botulinum toxin type A products?
   Net price pressure, safety-related practice changes, regulatory updates tied to pharmacovigilance, and supply continuity are the core commercial risks.

5. Can a peak sales forecast be calculated here?
   A defensible numeric forecast requires sourced current sales/unit baselines, market size inputs, and a dated lifecycle plan; those datasets are not available in this chat context.

References

[1] ClinicalTrials.gov. (n.d.). AbobotulinumtoxinA (search results). https://clinicaltrials.gov/
[2] EU Clinical Trials Register. (n.d.). AbobotulinumtoxinA (search results). https://www.clinicaltrialsregister.eu/
[3] WHO ICTRP. (n.d.). AbobotulinumtoxinA (search results). https://trialsearch.who.int/